Focus: AskBio is a 5,000+ employee biotechnology company headquartered in Durham, NC, specializing in cellular and protein-based therapies with a focus on gene therapy for rare genetic and neurological diseases. Founded in 2020, the company operates as a mid-cap biotech with an active pipeline spanning oncology, neurology, and cardiac indications.
Profile data last refreshed 2h ago · AI intelligence enriched 6d ago
AskBio offers a rare-disease gene therapy opportunity with clinical traction and R&D depth, but limited hiring and early pipeline maturity mean this is best for mission-driven scientists willing to bet on long-term value creation over near-term commercial upside.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AskBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AskBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
AskBio Phase II heart failure trial of umiposgene parvec win - The Pharma Letter
AskBio Phase II heart failure trial of umiposgene parvec win The Pharma Letter
AskBio Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
AskBio Number of Employees 2026 | Employee Count & Headcount Data Revelio Labs
Prime Medicine Hopes FDA Will Consider 'Novel' Approval Path for First Candidate - Precision Medicine Online
Prime Medicine Hopes FDA Will Consider 'Novel' Approval Path for First Candidate Precision Medicine Online
Front-Line Sac-TMT Shows Benefit in PD-L1-Positive Lung Cancer as Chinese Regulators Mull Approval - Precision Medicine Online
Front-Line Sac-TMT Shows Benefit in PD-L1-Positive Lung Cancer as Chinese Regulators Mull Approval Precision Medicine Online
European Biotechs Developing Next-Generation Cell and Gene Therapy Manufacturing Technologies - PharmTech.com
European Biotechs Developing Next-Generation Cell and Gene Therapy Manufacturing Technologies PharmTech.com
Bayer to buy eye-drug developer Perfuse Therapeutics for up to $2.45 billion - MSN
Bayer to buy eye-drug developer Perfuse Therapeutics for up to $2.45 billion MSN
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo